The evolution of the cannabis market in the U.S. has been a mixed bag for multistate operators (MSOs) and their investors thus far, with revenue growing but stock prices falling. As companies and investors are eager for any progress on decriminalization at the federal level, state-level sales are what's keeping some afloat.

Cresco Labs (OTC: CRLBF) is one of those MSOs leaning on state sales to drive revenue growth and provide returns for investors. After the company released solid second-quarter earnings in August, average analyst projections have Cresco Labs stock climbing 130% over the next year. But should investors buy in on that projection?

Image source: Getty Images.

Continue reading

Source Fool.com